• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»ALLEGORY

FDA accepts Genentech’s Gazyva application for SLE, what it means for lupus treatment

By Pallavi Madhiraju on April 21, 2026   Pharma & Biotech  

FDA accepts Genentech’s Gazyva application for SLE, what it means for lupus treatment

FDA accepts Genentech’s Gazyva filing for systemic lupus erythematosus. Read what the ALLEGORY data could mean for lupus treatment in 2026.

Recent Posts

  • Can Rznomics turn RZ-001 into a breakthrough therapy for hepatocellular carcinoma?
  • FDA accepts Genentech’s Gazyva application for SLE, what it means for lupus treatment
  • Why Lantern Pharma’s LP-300 data in EGFR L858R NSCLC could reshape the post-osimertinib debate
  • Can Hologic’s breast imaging AI close one of mammography’s most stubborn detection gaps?
  • Takara Bio USA unveils AACR benchmark data for Trekker FX, but will cancer labs switch?
  • Palleon Pharmaceuticals tests B7-H3-targeted sialidase in ovarian cancer, what changes now?
  • Could Entos Pharmaceuticals’ Fusogenix platform open a real path to treatment in L-CMD?
  • What AbCellera’s upcoming ABCL635 Phase 1 data could reveal about the future of menopause treatment
  • Can Debiopharm turn a Fast Track win into a real ovarian cancer breakthrough?
  • Why Dana-Farber’s Enhertu biomarker study could change metastatic breast cancer diagnostics
  • Why CytoDyn Inc.’s leronlimab data could reshape TNBC immunotherapy strategies
  • Akari Therapeutics Plc advances AKTX-101 as RNA splicing ADC targets TROP2 resistance in oncology
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes